Your browser doesn't support javascript.
loading
Paracrine nitric oxide induces expression of cardiac sarcomeric proteins in adult progenitor cells through soluble guanylyl cyclase/cyclic-guanosine monophosphate and Wnt/ß-catenin inhibition.
De Pauw, Aurelia; Massion, Paul; Sekkali, Belaid; Andre, Emilie; Dubroca, Caroline; Kmecova, Jana; Bouzin, Caroline; Friart, Ann; Sibille, Catherine; Gilon, Patrick; De Mulder, Delphine; Esfahani, Hrag; Strapart, Adrien; Martherus, Ruben; Payen, Valéry; Sonveaux, Pierre; Brouckaert, Peter; Janssens, Stefan; Balligand, Jean-Luc.
Afiliação
  • De Pauw A; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Massion P; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Sekkali B; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Andre E; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Dubroca C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Kmecova J; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Bouzin C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Friart A; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Sibille C; Department of Human Genetics, Cliniques Saint-Luc, Université Catholique de Louvain, 10 avenue Hippocrate, 1200 Brussels, Belgium.
  • Gilon P; Pole of Endocrinology, Diabetes and Nutrition (EDIN), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, B1.55.06, 55 avenue Hippocrate, 1200 Brussels, Belgium.
  • De Mulder D; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Esfahani H; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Strapart A; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Martherus R; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Payen V; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Sonveaux P; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium.
  • Brouckaert P; Department of Biomedical Molecular Biology, Universiteit Gent, Technologiepark 927, 9052 Gent, Belgium.
  • Janssens S; Department of Cardiology, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium.
  • Balligand JL; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Departement de Medecine Interne et Cliniques Saint-Luc, Université Catholique de Louvain, B1.53.09, 52 Ave. Mounier, 1200 Brussels, Belgium jl.balligand@uclouvain.be.
Cardiovasc Res ; 112(1): 478-90, 2016 10.
Article em En | MEDLINE | ID: mdl-27520736
AIM: Cardiac progenitor cells (CPC) from adult hearts can differentiate to several cell types composing the myocardium but the underlying molecular pathways are poorly characterized. We examined the role of paracrine nitric oxide (NO) in the specification of CPC to the cardiac lineage, particularly through its inhibition of the canonical Wnt/ß-catenin pathway, a critical step preceding cardiac differentiation. METHODS AND RESULTS: Sca1 + CPC from adult mouse hearts were isolated by magnetic-activated cell sorting and clonally expanded. Pharmacologic NO donors increased their expression of cardiac myocyte-specific sarcomeric proteins in a concentration and time-dependent manner. The optimal time window for NO efficacy coincided with up-regulation of CPC expression of Gucy1a3 (coding the alpha1 subunit of guanylyl cyclase). The effect of paracrine NO was reproduced in vitro upon co-culture of CPC with cardiac myocytes expressing a transgenic NOS3 (endothelial nitric oxide synthase) and in vivo upon injection of CPC in infarcted hearts from cardiac-specific NOS3 transgenic mice. In mono- and co-cultures, this effect was abrogated upon inhibition of soluble guanylyl cyclase or nitric oxide synthase, and was lost in CPC genetically deficient in Gucy1a3. Mechanistically, NO inhibits the constitutive activity of the canonical Wnt/ß-catenin in CPC and in cell reporter assays in a guanylyl cyclase-dependent fashion. This was paralleled with decreased expression of ß-catenin and down-regulation of Wnt target genes in CPC and abrogated in CPC with a stabilized, non-inhibitable ß-catenin. CONCLUSIONS: Exogenous or paracrine sources of NO promote the specification towards the myocyte lineage and expression of cardiac sarcomeric proteins of adult CPC. This is contingent upon the expression and activity of the alpha1 subunit of guanylyl cyclase in CPC that is necessary for NO-mediated inhibition of the canonical Wnt/ß-catenin pathway.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcômeros / Diferenciação Celular / GMP Cíclico / Comunicação Parácrina / Miócitos Cardíacos / Beta Catenina / Células-Tronco Adultas / Via de Sinalização Wnt / Guanilil Ciclase Solúvel / Óxido Nítrico Limite: Animals Idioma: En Revista: Cardiovasc Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcômeros / Diferenciação Celular / GMP Cíclico / Comunicação Parácrina / Miócitos Cardíacos / Beta Catenina / Células-Tronco Adultas / Via de Sinalização Wnt / Guanilil Ciclase Solúvel / Óxido Nítrico Limite: Animals Idioma: En Revista: Cardiovasc Res Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica